Endocrine Society Advocates for Increased NIH Funding

Join our online campaign to share our message with your representative and senators

The U.S. Congress is currently considering funding for fiscal year (FY) 2023, which begins October 1. The Endocrine Society is urging Congress to provide $50 billion for the National Institutes of Health (NIH) for fiscal year (FY) 2023, a 7.9% increase from the FY 2022 funding level.

To increase funding for the NIH, it is critical that all U.S. representatives and senators hear from their constituents about this issue. We encourage all U.S. Endocrine Society members to join our campaign by visiting www.endocrine.org/takeaction. Taking action will only take a minute of your time, but it will have an impact as all congressional offices constantly monitor and count constituent mail.

The Endocrine Society is one of the leading advocates for NIH funding helping Congress to understand that steady funding is essential to maintain momentum from previous investments and support new opportunities for life-saving medical research. Last year, we helped secure a $2.25 billion increase for the NIH, continuing a seven-year trend of increases to the NIH budget.

The Endocrine Society is one of the leading advocates for NIH funding helping Congress to understand that steady funding is essential to maintain momentum from previous investments and support new opportunities for life-saving medical research.

This year’s increase would support early career researchers who have been impacted by the pandemic and fund innovative investigator-initiated research projects. We also continue to share with Congress the importance of securing a base funding increase for the NIH exclusive of funding for the new Advanced Research Projects Agency for Health (ARPA-H). While ARPA-H may have benefit to endocrine-related research, we have advocated that its funding must not siphon funds from investigator-initiated research at the NIH.

If the research community can amplify these messages, we can secure a significant increase in FY 2023. Take action today!

You may also like

  • August 2024 Endocrine Society Advocacy Update

    Revised Version of TROA Passes House Ways & Means Committee On June 27, 2024, the House Ways and Means Committee passed a revised version of the Treat and Reduce Obesity Act (TROA), legislation that would allow Medicare coverage of anti-obesity medications (AOMs), which currently is prohibited under law. The version that passed would only allow…

  • Endocrine Society Continues Global EDC Advocacy; EU Election Results Leaves Outcomes for EDC Legislation Uncertain  

    On June 17, the Endocrine Society joined delegations from dozens of countries gathered in Geneva, Switzerland, for the third session of an ad hoc open-ended working group (OEWG) convened under the United Nations Environment Programme (UNEP) to develop proposals to establish a new science policy panel charged with helping to inform governments, companies, farmers and…

Find more in